Goals for Epilepsy Clinic Visits Trial

StatusActive, Not Recruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing Show 5 more changesShow less
    • Primary completion date changed from estimate of Sep 1, 2026 to Jul 22, 2026
    • Study completion moved earlier from Jan 1, 2027 to Oct 20, 2026
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 3 of 4 entries
    • Site details revised
  2. Enrollment target: 162 to 152
    • Site contact updated
    v7
  3. Primary completion date: Dec 1, 2026 to Sep 1, 2026v6
  4. Primary completion date: Sep 1, 2026 to Dec 1, 2026v5
  5. Site contact updatedv4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Aug 18, 2023 to Sep 27, 2023
    • Primary completion date: Dec 2026 to Sep 1, 2026
    • Study completion date: Dec 2026 to Jan 1, 2027
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 2023 to Aug 18, 2023
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this project is to conduct a trial to assess whether patients that receive a tablet-based waiting room priority communication tool (the "Epilepsy Visit Planner") have improved outcomes compared to patients that do not receive the tool. The project's hypotheses are: * Patients that receive the Epilepsy Visit Planner will have improved patient-provider communication compared to the non-planner group. * Patients that receive the Epilepsy Visit Planner will have improved quality of life scores. * The Epilepsy Visit Planner will score highly on process measures of feasibility and acceptability, demonstrating suitability for future larger scale study. Additionally, there is a related survey project that is not part of the clinical trial and will not be included in this registration information.
Trial Details
NCT Number NCT05928598
Lead Sponsor University of Michigan
Collaborators: National Institute of Neurological Disorders and Stroke (NINDS)
Conditions
(from sponsor)		 Drug Resistant Epilepsy
Related terms Drug Resistant Epilepsy
Enrollment 152 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov